Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotyp...
Main Authors: | Susanna Esposito, Nicola Principi |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2015/591580 |
Similar Items
-
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01) -
13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017-03-01) -
Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
by: Corinne Levy, et al.
Published: (2021-08-01) -
Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01) -
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)